ImmunoGen's anti-B4-bR
Executive Summary
Orphan drug status granted to anti-B4-blocked ricin for the treatment of non-Hodgkin's lymphoma and acute lymphocytic leukemia. The compound employs a toxin linked to a cancer-seeking antibody. ImmunoGen began Phase I studies in September at the Dana-Farber Cancer Institute....